Navidea Biopharmaceuticals: $11.95M Sale and Subchapter V Liquidation Plan Confirmed
Navidea Biopharmaceuticals, Inc., the Columbus biotech that developed the Lymphoseek lymph node mapping agent drugs.com: Lymphoseek lymph node mapping agent (outside source, not verified by ElevenFlo) and sold its North American rights to Cardinal Health for $83 million in 2017 businesswire.com: $83 million in 2017 (outside source, not verified by ElevenFlo), has confirmed a Subchapter V plan of liquidation less than eight months after filing. Judge J. Kate Stickles entered the Findings of Fact, Conclusions of Law, and Order Confirming Subchapter V Debtor's Second Amended Plan of Liquidation With Technical Modifications Dkt. 376 on May 27, 2026, four days after a May 22 bench ruling and six days after the May 21 confirmation hearing, in Case No. 25-11779 before the U.S. Bankruptcy Court for the District of Delaware. The plan distributes residual cash from Navidea's February 11, 2026 section 363 sale to Cardinal Health 414, LLC for $11.95 million, embeds a Scott Settlement that reduces disputed insider postpetition interest and fees by roughly $399,000, and channels remaining recoveries through a Plan Administrator and a Litigation Trust. A derivative Shareholders' Bankruptcy Action against insider lender John Kimball Scott Jr. proceeds in parallel in Adversary Proceeding No. 26-50226.
| Debtor(s) | Navidea Biopharmaceuticals, Inc. |
| Court | U.S. Bankruptcy Court, District of Delaware |
| Case Number | 25-11779 |
| Judge | Hon. J. Kate Stickles |
Plan Confirmation and Section 1191(b) Cramdown
Judge Stickles confirmed the Second Amended Plan of Liquidation with technical modifications on May 27, 2026, after the May 21 confirmation hearing Dkt. 370 and a May 22 bench ruling Dkt. 373. The court overruled any objections that were not withdrawn, resolved, waived, or settled "on the merits in full." The same order resolved the Scott Settlement, addressed third-party releases, and approved Edward Burr as Plan Administrator.
All four classes under the confirmed plan are impaired and were deemed to reject, so Navidea did not solicit votes and proceeded under the Subchapter V cramdown standard in section 1191(b) of the Bankruptcy Code Dkt. 355. The debtor's confirmation brief argued the plan satisfies the section's fair-and-equitable test and that the shareholder objection — the only objection that reached confirmation — was self-serving and lacked merit.
Stockholder Harry Shualy objected to confirmation Dkt. 348 on May 13, 2026, arguing that the Litigation Trust was unnecessary and duplicative of the derivative Shareholders' Bankruptcy Action, that the plan and Scott Settlement were not proposed in good faith, and that the plan was not fair and equitable. The debtor's May 18 confirmation brief responded that an independent Litigation Trustee with a duty to pursue all estate claims was preferable to letting shareholders "have an outsized voice in the direction of and resolution of the Estate's litigation claims." A supporting declaration from Edward Burr Dkt. 356 and a reply in support of confirmation from Scott Dkt. 364 accompanied the brief.
The plan provides for consensual third-party releases on an opt-in basis. Claim holders and known registered holders and nominees had to return a Release Opt-In Election Form by May 13, 2026; the debtor reported sixteen returned forms. Epiq Corporate Restructuring, LLC filed its tabulation declaration Dkt. 357 on May 18.
Confirmed Class Treatment and Liquidation Funding
The confirmed plan classifies all claims and interests into four impaired classes, none of which were entitled to vote because none received any consensual treatment under the Second Amended Plan of Liquidation Dkt. 339. The four classes carry the following treatment.
| Class | Description | Treatment |
|---|---|---|
| 1 | Scott Secured Claim | Paid the Modified Postpetition Interest Amount of $494,304 and the Modified Fee Amount of $452,842.25 on the Effective Date, subject to disgorgement if the Shareholders' Bankruptcy Action succeeds |
Scott Settlement and Insider Debt Resolution
The plan embeds the Scott Settlement at Article 1.9, which materially reduces the disputed-claim amounts that had been placed in reserve under the March 21, 2026 order Dkt. 297 authorizing payment of Scott's prepetition secured debt. That earlier order directed payment of $7,795,479.51 of stipulated prepetition principal and interest to Scott and placed $1,345,970.60 in a Disputed Claims Reserve to cover $761,365.91 of disputed postpetition interest and $584,604.69 of asserted Secured Note Fees; an amended order Dkt. 300 followed on March 23.
Under the confirmed plan Dkt. 339, postpetition interest on the Scott loans is reduced from $761,365.91 to a Modified Postpetition Interest Amount of $494,304. The Secured Note Fees are reduced from $584,604.69 to a Modified Fee Amount of $452,842.25 — $400,000 to Fox Rothschild LLP and $52,842.25 to Winstead PC. The Effective Date Payment of $947,146.25 is paid directly to Scott and his counsel on the Effective Date, and the remaining $398,824 held in the Disputed Claims Reserve reverts to the debtor.
All payments under the Scott Settlement are subject to disgorgement if the derivative Shareholders' Bankruptcy Action ultimately results in disallowance of Scott's underlying secured claim. Scott also agreed not to object to fee applications filed by the debtor's professionals or the Subchapter V trustee, is designated an Exculpated Party under the plan, and is barred together with his counsel from seeking additional reimbursement beyond the Modified Fee Amount. The reduced amounts in the Disputed Claims Reserve are also protected from surcharge under section 506(c) of the Bankruptcy Code without written consent. The plan terms condition the entire Scott Settlement on the court's approval of each of subsections (a) through (h), so if the court had declined to approve any one (other than the payment subsection), the settlement would not have been binding.
Scott's reply in support of confirmation Dkt. 364 argued that he had voluntarily conceded roughly $399,000 by reducing his postpetition interest and fee claims, that his investments and bankruptcy financing had preserved Navidea's operations and enabled the orderly sale that generated nearly $12 million in proceeds, and that the shareholders' claims were "economically irrational" because they failed to participate in the bidding process despite contending the company was worth $60 million.
Shareholders' Bankruptcy Action and Derivative Standing
A parallel adversary proceeding — defined in the confirmed plan as the "Shareholders' Bankruptcy Action" — runs alongside the confirmed plan. On March 30, 2026, the court granted shareholder Harry Shualy derivative standing Dkt. 309 to prosecute estate causes of action against Scott. The Estate of Navidea, by and through Shualy as derivative plaintiff, then filed Adversary Proceeding No. 26-50226 Dkt. 308 on March 31 asserting recharacterization, equitable subordination, and avoidance claims against Scott — even after the Subchapter V trustee's earlier investigation found no viable claims to recharacterize or subordinate Scott's prepetition debt.
The plan distributes recoveries Dkt. 339 from the adversary action on a stacked basis: 80% of net proceeds to Class 2 general unsecured claims (after payment of Administrative Expenses and the Scott Secured Claim), with the remaining 20% split between Class 3 preferred and Class 4 common equity. The disgorgement mechanism in the Scott Settlement is the only way Scott's Effective Date Payment can be clawed back, and it triggers only on a successful Shareholders' Bankruptcy Action Determination that disallows Scott's underlying secured claim.
The plan also empowers the Litigation Trust to pursue other "Litigation Trust Actions" that are not part of the derivative shareholder action, with proceeds distributed on the same waterfall.
February 2026 Section 363 Sale to Cardinal Health
The confirmed plan is a follow-on to the section 363 sale that closed on February 11, 2026. Navidea filed its sale motion Dkt. 146 on November 24, 2025, signaling that it believed either a prompt sale closing or a plan transaction was needed and structuring bids so any transaction would cover the prepetition secured debt, DIP obligations, and other required liabilities. The court entered the bidding procedures order Dkt. 166 on December 11.
Investment banker SSG Advisors, LLC ran the marketing, and the Zoom auction Dkt. 215 was held on January 22, 2026. Cardinal Health 414, LLC, which had been the exclusive U.S. distributor for Lymphoseek before the 2017 asset sale businesswire.com: $83 million in 2017 (outside source, not verified by ElevenFlo), submitted the successful bid; Scott was the backup bidder with a credit bid of approximately $10.6 million. Cardinal increased its initial bid by $600,000 during the auction, and the revised bid totaled $11.95 million in cash plus assumption of certain liabilities and cure costs. With assumed cure liabilities, the total bid value reached at least $12,102,657.55.
The sale order Dkt. 232 entered January 30, 2026 approved the transfer of substantially all assets free and clear of liens, claims, interests, and encumbrances, with those interests attaching to net sale proceeds. The transaction closed on February 11, with Navidea paying all DIP obligations in full — $1,129,165.89 of principal and interest plus $25,883.34 of fees and expenses — and escrowing $737,918.09 Dkt. 244 of SSG's compensation pending final fee approval.
Insider DIP Financing and Trustee Investigation
John Kimball Scott Jr. — Navidea's largest secured creditor by petition date and the sole remaining director by August 2025 — provided the company's debtor-in-possession financing. The initial DIP motion Dkt. 12 proposed up to $940,000 with an initial draw under an interim order, additional funding of up to $640,000 after a final order, 10% annual interest paid in kind, and a 5% default-rate premium. The interim DIP order Dkt. 32 was entered October 9, 2025.
The final DIP order Dkt. 122 entered November 7, 2025 increased the facility to up to $1.6 million, kept the 10% PIK rate plus the 5% default-rate increment, and granted Scott first-priority priming liens and superpriority claims. The order deliberately preserved a challenge-and-investigation track around Scott's insider debt: parties in interest had until December 30, 2025 to commence a challenge; Subchapter V trustee David M. Klauder had until January 5, 2026 to file an investigation report; and up to $100,000 of the DIP budget was reserved for that investigation. Stockholders could seek derivative standing depending on the report's findings.
Klauder's investigation report Dkt. 196 filed January 9, 2026, broke Scott's roughly $7,791,497 prepetition secured exposure into a first loan at roughly $1.59 million, a third loan at $885,071, a fourth loan at $3.36 million, and a fifth loan at $1.96 million, with interest rates ranging from 8% on the first and third loans to 18% on the fourth and 10% on the fifth. After reviewing loan and security documents, board materials, financing statements, bank records, settlements, and witness interviews, Klauder concluded that no viable recharacterization, equitable-subordination, or avoidance claims existed against Scott's prepetition secured debt, and that the loans were legal, valid, binding, documented, perfected, used to fund operations, and not the product of inequitable conduct.
Stockholder Harry Shualy ultimately disputed that conclusion. His February 18, 2026 objection Dkt. 249 to the debtor's motion to pay Scott from sale proceeds criticized the trustee investigation as procedurally incomplete, asked the court to deny payment or place the payoff in reserve, and was followed by a separate motion for derivative standing . The debtor's February 20 omnibus reply and the Subchapter V trustee's February 20 response followed.
Path to Filing: Cardinal Health Sale, Litigation, and RA Trial Failure
Navidea's October 1, 2025 chapter 11 filing fiercebiotech.com: October 1, 2025 chapter 11 filing (outside source, not verified by ElevenFlo) followed nearly a decade of litigation, asset sales, and clinical setbacks. The First Day Declaration Dkt. 14 by independent director Edward Burr described Navidea as a pre-revenue research and development company with one full-time and two part-time employees by the petition date.
The company changed its name from Neoprobe Corporation to Navidea Biopharmaceuticals in January 2012 and built its diagnostic platform around Lymphoseek (technetium Tc 99m tilmanocept), a radiopharmaceutical that binds to CD206 mannose receptors on macrophages and dendritic cells. The FDA approved Lymphoseek for breast cancer and melanoma in March 2013 — the first new lymph node mapping agent drugs.com: Lymphoseek lymph node mapping agent (outside source, not verified by ElevenFlo) approved in more than 30 years — and later expanded approval to pediatric patients newsroom.cardinalhealth.com: expanded approval to pediatric patients (outside source, not verified by ElevenFlo) with melanoma, rhabdomyosarcoma, and other solid tumors in 2021. Clinical studies showed a 96% lymph node detection rate in pediatric patients.
Professional Retentions
The confirmed plan identifies the same professional team that handled the case from filing through confirmation. Pashman Stein Walder Hayden, P.C. serves as debtor's counsel; SSG Advisors, LLC is investment banker; and Epiq Corporate Restructuring, LLC is claims and noticing agent. The Office of the United States Trustee appointed David M. Klauder as Subchapter V trustee, with Bielli & Klauder, LLC as his counsel.
The court entered first interim fee orders Dkt. 261 approving Klauder's and Bielli & Klauder's Dkt. 262 compensation on February 24, 2026 and second interim approvals Dkt. 351 for Pashman Stein, Klauder, and Bielli & Klauder on May 14, 2026. SSG's $737,918.09 sale-related compensation remains in escrow pending final fee approval. Scott's secured-note professional fees were resolved through the Scott Settlement: $400,000 to Fox Rothschild LLP and $52,842.25 to Winstead PC.
Key Timeline
| Date | Event |
|---|---|
| October 1, 2025 | Voluntary Subchapter V petition filed |
| October 7, 2025 | First Day Declaration and DIP motion filed |
| October 9, 2025 | Interim DIP order ($255,000) entered |
Frequently Asked Questions
What did the May 27, 2026 confirmation order do?
Judge J. Kate Stickles entered the Findings of Fact, Conclusions of Law, and Order Confirming Subchapter V Debtor's Second Amended Plan of Liquidation With Technical Modifications on May 27, 2026, approving Navidea's liquidating Subchapter V plan under section 1191(b) cramdown. All four impaired classes were deemed to reject, no solicitation occurred, and any objections that were not withdrawn, resolved, waived, or settled were overruled on the merits in full. The order also approves the embedded Scott Settlement and appoints Edward Burr as Plan Administrator.
How are creditors and equity holders treated under the confirmed plan?
Class 1 (Scott Secured Claim) receives a $947,146.25 Effective Date Payment representing reduced postpetition interest and fees. Class 2 (General Unsecured Claims) receives any Plan Administrator Surplus plus 80% of net Shareholders' Bankruptcy Action and Litigation Trust recoveries pro rata. Class 3 (Preferred Stock) and Class 4 (Common Stock) split the remaining 20% of those net recoveries pro rata, but only after Administrative Expenses and the Scott Secured Claim are paid.
What is the Scott Settlement?
The Scott Settlement, embedded at Article 1.9 of the plan, reduces Scott's disputed postpetition interest from $761,365.91 to $494,304 and his asserted Secured Note Fees from $584,604.69 to $452,842.25, returning $398,824 of the Disputed Claims Reserve to the debtor. Scott and his counsel — Fox Rothschild LLP ($400,000) and Winstead PC ($52,842.25) — are paid directly on the Effective Date. All payments are subject to disgorgement if the derivative Shareholders' Bankruptcy Action ultimately disallows the underlying Scott Secured Claim. Scott is also designated an Exculpated Party under the plan.
What is the Shareholders' Bankruptcy Action?
It is Adversary Proceeding No. 26-50226, filed March 31, 2026 by stockholder Harry Shualy as derivative plaintiff after the court granted derivative standing on March 30. The complaint asserts recharacterization, equitable subordination, and avoidance claims against Scott on behalf of the Navidea estate, notwithstanding the Subchapter V trustee's January 9 finding that no viable claims existed. Class 2 general unsecured creditors receive 80% of net recoveries from the action; Classes 3 and 4 split the remaining 20%.
Who is the Plan Administrator?
Edward Burr, Navidea's independent director appointed in August 2025, serves as Plan Administrator. He oversees the Claims Reconciliation Process, distributions from the Plan Administrator Reserve, quarterly post-confirmation reports to the U.S. Trustee and Subchapter V trustee David M. Klauder, objections to claims, and disposition of remaining estate assets free and clear of liens.